You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

Leading medical-scientific event on Hemophilia held in Trieste, Italy

Kedrion-organized congress put replacement therapy, personalization and access to care in the spotlight

read more 

EVENTS

Kedrion scientific symposium at the 2019 PNS Conference in Genoa, Italy

A chance for world Key Opinion Leaders to debate possible new therapies for the treatment of CIPN

read more 

PLASMA & BIOTHERAPIES

First patient enrolled and treated in Kedrion’s CARES10 clinical study

Phase 3 study to assess efficacy, safety and pharmacokinetics of a 10% IVIg in the treatment of adult PID patients

read more 
  1. EVENTS - 14-02-2018

    Kedrion Biopharma joins Columbia University to celebrate 50 years of Anti-D

    Since 1968, billions of babies have been saved from Hemolytic Disease of the Fetus and Newborn

    read more 
  2. CORPORATE - 10-01-2018

    Hemophilia: Kedrion signs on to groundbreaking PARTNERS programme

    Goal is to improve access to replacement therapies for coagulation disorders in Europe

    read more 
  3. EVENTS - 09-11-2017

    Kedrion Biopharma joins IPOPI in supporting patients with APP PID Genius

    This new APP, presented at the IPIC Congress in Dubai, will be the personal assistant to people living with PIDs

    read more 
  4. CORPORATE - 31-10-2017

    Kedrion and Cerus enter distribution agreement for INTERCEPT in Italy

    Agreement covers complete INTERCEPT product line: platelets, plasma and red blood cells

    read more 

Pages

For more information please contact: pressoffice@kedrion.com